Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Enterprise Value (2016 - 2025)

Voyager Therapeutics' Enterprise Value history spans 11 years, with the latest figure at -$196.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 26.34% year-over-year to -$196.4 million; the TTM value through Dec 2025 reached -$196.4 million, up 26.34%, while the annual FY2025 figure was -$196.4 million, 26.34% up from the prior year.
  • Enterprise Value for Q4 2025 was -$196.4 million at Voyager Therapeutics, down from -$163.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$34.8 million in Q3 2022 and bottomed at -$371.0 million in Q2 2024.
  • The 5-year median for Enterprise Value is -$192.1 million (2023), against an average of -$192.6 million.
  • The largest annual shift saw Enterprise Value skyrocketed 71.38% in 2022 before it plummeted 439.61% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$132.5 million in 2021, then grew by 10.33% to -$118.8 million in 2022, then crashed by 94.26% to -$230.9 million in 2023, then decreased by 15.51% to -$266.7 million in 2024, then increased by 26.34% to -$196.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Enterprise Value are -$196.4 million (Q4 2025), -$163.8 million (Q3 2025), and -$215.6 million (Q2 2025).